Extended use of P504S Positive Primary Circulating Prostate Cell Detection to Determine the Need for Initial Prostate Biopsy in a Prostate Cancer Screening Program in Chile |
Murray, Nigel P.
(Hospital Carabineros of Chile)
Reyes, Eduardo (Hospital Carabineros of Chile) Fuentealba, Cynthia (Hospital Carabineros of Chile) Jacob, Omar (Hospital Carabineros of Chile) Orellana, Nelson (Hospital Carabineros of Chile) |
1 | Aus G (1994) Prostate cancer: mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl, 167, 1-41. |
2 | Beach R, Gown AM, Peralta-Venturina MN et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol 26, 1588-96. DOI ScienceOn |
3 | Borgen E, Naume B, Nesland JM, et al (1999) Standardization of the immunocitochemical detection of cancer cells in bone marrow and blood: Establishment of objective criteria for the evaluation of immunostained cells. ISHAGE Cytotherapy, 5, 377-88. |
4 | Bozeman CB, Carver BS, Eastman JA et al (2002). Treatment of chronic prostatitis lowers serum PSA. J Urol, 167, 1723-26. DOI ScienceOn |
5 | Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor ce-lls in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91. DOI ScienceOn |
6 | De Visschere P, Oosterlink W, De Meerleer G et al (2010). Clinical and imaging tools in the early diagnosis of prostate cancer: a review. JBR-BTR, 93, 62-70. |
7 | Draisma G, Boer R, Otto SJ et al (2003). Active treatment for PSA screening detected prostate cancer. J Natl Cancer Inst. 95, 868-78. DOI ScienceOn |
8 | Epstein JI, Walsh PC, Carmichael M et al (1994). Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA, 271, 368-74. DOI ScienceOn |
9 | Eschwege P, Moutereau S, Droupy S, et al (2009). Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer. 100, 608-10. DOI |
10 | Fehm T, Sotomayer EF, Meng S, et al (2005). Methods for isolating epi-thelial cells and criteria for their classification as carcinoma cells. Cytotherapy, 7, 171-85. DOI |
11 | Fizazi K, Morat L, Chauveinc L, et al (2007). High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol, 18, 518-21. |
12 | Fu-Bin Wang (2011). A higher number of CTCs in peripheral blood indicates poor prognosis in prostate cancer patients:A meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35. |
13 | Helo P, Cronin AM, Danila DC, et al (2009). Circulating pros-tate tumor cells detected by RT-PCR in men with localized or castrate refractory prostate cancer: concordance with CellSearch assay and association with bone metastasis and with survival. Clin Chem, 55, 765-73. DOI ScienceOn |
14 | Mikolajczyk SD, Millar LS, Tsinberg P, et al (2011). Detection of EpCAM negative and cytokeratin negative circulating tumor cells in peripheral blood. J Oncol, 10, 1155. |
15 | Murray NP, Reyes E, Badinez et al (2013). Circulating prostate cells found in men with benign prostate disease are P504S negative. J Oncol, 10, 1155. |
16 | Moll R, Divo M, Langbein L (2008). The human keratins: biology and pathology. Histochem Cell Biol, 129, 705-33. DOI ScienceOn |
17 | Moreno JG, Croce CM, Fischer R,et al (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2. |
18 | Murray NP, Calaf GM, Badinez L et al (2010). P504S expressing circulating prostate cells as a marker for prostate cancer. Oncol Reports, 24, 687-692. |
19 | Murray NP, Reyes E, Orellana N et al (2013a). Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. Sci World J, 10, 1155. |
20 | Murray NP, Reyes E, Orellana N et al (2014). A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. BioMed Research Int, 10, 1155. |
21 | Osman I, Scher HI, Drobnjak M, et al (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res, 7, 2643-7. |
22 | Panteleakou Z, Lembessis P. Sourla A, et al (2009). Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15, 101-14. |
23 | Par Kah D, Lal M, Hashmi AH et al (2014). Utility of DRE, serum PSA and TRUS in the detection of prostate cancer: A developing Country Perspective. Asian Pac J Cancer Prev, 15, 3087-91. DOI |
24 | Raimondi C, Gradilone A, Naso G, et al (2011). Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat, 130, 449-55. DOI |
25 | Paterlini-Brechot P, Benali NL (2007). Circulating tumor cells detection: clinical impact and future directions. Cancer Letters, 2, 180-204. |
26 | Postma R, Schroeder FH (2005). Screening for prostate cancer. Eur J Cancer, 41, 825-33. DOI ScienceOn |
27 | Pungalia RS, D'Amico AV, Catalona WJ et al (2006). Impact of age, benign prostatic hyperplasia and cancer on PSA level. Cancer, 106, 1507-113. DOI |
28 | Rietbergen JB, Kruger AE, Krause R, Schroder F (1997). Complications of transrectal ultrasound guided systematic sextant biopsies of prostate: evaluation of complication rates and risk factors within a population based screening population. Urol, 49, 875-880. DOI ScienceOn |
29 | Rubin MA, Zhou M, Dhanasekaran SM (2002). Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287, 1662-70. DOI ScienceOn |
30 | Schaffer DR, Leversha MA, Danila DC (2007). Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clin Cancer Res, 13, 2023-9. DOI |
31 | Schroder FHJ, van der Cruijsen-Koeter HJ, de Koning AN et al (2000). Prostate cancer detection at low PSA. J Urol, 163, 806-12. DOI ScienceOn |
32 | Stott SL, Lee RJ, Nagrath S, Yu M, et al (2010). Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med, 25, 25 |
33 | Zhou M, Chinnaiyan AM, Lleer CG et al (2002). Alpha-methylacyl-CoA racemase: a novel tumor. Surg Pathol, 26, 926-31. DOI ScienceOn |
34 | Thompson IM, Goodman PJ, Tangen CM et al (2003). The influence of finisteride on the development of prostate cancer. N Eng J Med, 349, 215-24. DOI ScienceOn |
35 | Went PT, Lugli A, Meier S et al (2004). Frequent EpCam protein expression in human carcinomas. Hum Pathol, 1, 122-8. |
36 | Zheng XY, Zhang P, Xie LP et al (2014). PSAV and PSAV per intial volume for early detection of prostate cancer. Asian Pac J Cancer Prev, 13, 5529-33. |